Gain Therapeutics (GANX) Depreciation and Depletion (2020 - 2025)
Gain Therapeutics has reported Depreciation and Depletion over the past 6 years, most recently at $16000.0 for Q4 2025.
- Quarterly results put Depreciation and Depletion at $16000.0 for Q4 2025, up 60.0% from a year ago — trailing twelve months through Dec 2025 was $45000.0 (up 21.62% YoY), and the annual figure for FY2025 was $45000.0, up 18.42%.
- Depreciation and Depletion for Q4 2025 was $16000.0 at Gain Therapeutics, up from $10000.0 in the prior quarter.
- Over the last five years, Depreciation and Depletion for GANX hit a ceiling of $17139.0 in Q2 2023 and a floor of $2158.0 in Q2 2021.
- Median Depreciation and Depletion over the past 5 years was $9000.0 (2023), compared with a mean of $8627.8.
- Biggest five-year swings in Depreciation and Depletion: skyrocketed 433.09% in 2022 and later tumbled 47.49% in 2024.
- Gain Therapeutics' Depreciation and Depletion stood at $5785.0 in 2021, then soared by 34.35% to $7772.0 in 2022, then grew by 15.8% to $9000.0 in 2023, then increased by 11.11% to $10000.0 in 2024, then surged by 60.0% to $16000.0 in 2025.
- The last three reported values for Depreciation and Depletion were $16000.0 (Q4 2025), $10000.0 (Q3 2025), and $10000.0 (Q2 2025) per Business Quant data.